secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001104659-22-113505
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q3 revenue $6.2M (+82% YoY); raises FY2022 guidance; secures $50M debt facility
--------------------------------------------------------------------------------

- Q3 revenue $6.2M (+82% YoY); US HF revenue $4.9M (+99% YoY) on expansion to 91 active implanting centers (from 38).
- Net loss $9.8M ($0.48 per share) vs $6.1M ($0.30) YoY; cash and equivalents $110.0M at quarter end.
- FY2022 guidance narrowed: revenue $21.8M-$22.3M (prior $20.5M-$23.0M); gross margin 76-77% (prior 75-76%).
- BeAT-HF trial reached required 320th event; full unblinding expected first half 2023.
- Entered $50M term loan with Innovatus; drew $7.5M at close; interest-only for 5 years, matures Jan 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922113505/0001104659-22-113505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922113505/tm2229314d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-113505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer